Cognizance Biomarkers, LLC is an early stage biotechnology company developing a cost-effective diagnostic blood test for discriminating patients with epilepsy. The test, called CARPE (CNS-specific Assay for Recurrent Paroxysmal Events), originated in the University of Pennsylvania, where in early clinical studies it precisely separated patients with known recurrent seizures from control subjects. The assay hinges on measurement of two molecules linked to the inflammatory response, sICAM5 and TARC, using high-resolution capture ELISA.
Cognizance Biomarkers was founded through UPstart, the University of Pennsylvania company incubator. The Company has been funded by the National Institute of Neurological Disorders and Stroke and occupies a research laboratory in the University City section of Philadelphia, PA.